End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
37.64 EUR | +0.82% | -1.30% | -18.79% |
30/05 | Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma | MT |
30/05 | Bristol Myers: FDA approval for Breyanzi | CF |
Sales 2024 * | 46.09B 42.5B 3,844B | Sales 2025 * | 46.06B 42.47B 3,842B | Capitalization | 83.29B 76.8B 6,948B |
---|---|---|---|---|---|
Net income 2024 * | -5.41B -4.99B -452B | Net income 2025 * | 10.22B 9.42B 852B | EV / Sales 2024 * | 2.65 x |
Net Debt 2024 * | 39.03B 35.99B 3,256B | Net Debt 2025 * | 31.68B 29.21B 2,642B | EV / Sales 2025 * | 2.5 x |
P/E ratio 2024 * |
-15.6
x | P/E ratio 2025 * |
7.77
x | Employees | 34,100 |
Yield 2024 * |
5.86% | Yield 2025 * |
6.15% | Free-Float | 69.27% |
Latest transcript on Bristol-Myers Squibb Company
1 day | +0.82% | ||
1 week | -1.30% | ||
1 month | -9.60% | ||
3 months | -19.49% | ||
6 months | -17.27% | ||
Current year | -18.79% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 01/15/01 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 20/19/20 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 20/19/20 |
Peter Arduini
BRD | Director/Board Member | 59 | 01/16/01 |
Derica Rice
BRD | Director/Board Member | 59 | 01/20/01 |
Date | Price | Change |
---|---|---|
31/24/31 | 37.64 | +0.82% |
30/24/30 | 37.34 | -0.40% |
29/24/29 | 37.48 | -0.44% |
28/24/28 | 37.65 | -1.52% |
27/24/27 | 38.23 | +0.25% |
End-of-day quote Wiener Boerse, May 31, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- BMY Stock
- BMYS Stock